PMID- 38337544
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240212
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 13
IP  - 3
DP  - 2024 Feb 1
TI  - Helicobacter pylori Eradication Therapy in Patients with Decreased Renal 
      Function: A Systematic Review.
LID - 10.3390/jcm13030850 [doi]
LID - 850
AB  - Background: There are concerns that Helicobacter pylori eradication therapy may 
      worsen kidney function in patients with decreased renal function. This study 
      aimed to systematically review the literature regarding Helicobacter pylori 
      eradication in patients with renal impairment. Methods: PubMed, the Cochrane 
      Library, and Igaku Chuo Zasshi were searched for comparative studies on H. pylori 
      eradication in patients with renal impairment. Results: Five articles were 
      included in this systematic review. According to a randomized trial comparing a 
      proton pump inhibitor (PPI) + clarithromycin + metronidazole and PPI + 
      clarithromycin + amoxicillin in patients with decreased renal function, the 
      incidence of acute renal failure was significantly lower in PPI + clarithromycin 
      + metronidazole (2%: 1/44) than in PPI + clarithromycin + amoxicillin (18%: 
      8/44). The eradication rate in PPI + clarithromycin + metronidazole (92.5%) was 
      significantly better than that in PPI + clarithromycin + amoxicillin (76.3%). 
      According to four reports on eradication treatment using PPI + clarithromycin + 
      amoxicillin in patients with and without decreased renal function, the 
      eradication rates and adverse effects were similar in both groups. Regarding dose 
      adjustment, three reports reduced the dose of antibiotics by half in patients 
      with a creatinine clearance of 30 mL/min or less. Conclusions: The regimen with 
      PPIs, clarithromycin, and metronidazole is recommended for renal impairment. The 
      combination of PPIs, clarithromycin, and amoxicillin, at reduced doses depending 
      on the renal function, is also a potential option.
FAU - Nishizawa, Toshihiro
AU  - Nishizawa T
AD  - Department of Gastroenterology and Hepatology, International University of Health 
      and Welfare, Narita Hospital, Narita 286-8520, Japan.
AD  - Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan.
FAU - Sano, Masaya
AU  - Sano M
AUID- ORCID: 0009-0005-8115-0362
AD  - Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan.
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara 259-1193, Japan.
FAU - Toyoshima, Osamu
AU  - Toyoshima O
AD  - Gastroenterology, Toyoshima Endoscopy Clinic, Tokyo 157-0066, Japan.
FAU - Suzuki, Hidekazu
AU  - Suzuki H
AUID- ORCID: 0000-0002-8994-6163
AD  - Division of Gastroenterology and Hepatology, Department of Internal Medicine, 
      Tokai University School of Medicine, Isehara 259-1193, Japan.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240201
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC10856467
OTO - NOTNLM
OT  - Helicobacter pylori
OT  - decreased renal function
OT  - eradication
OT  - renal impairment
OT  - systematic review
COIS- H.S. received scholarship funds for the research from Biofermin Co. (Kobe, Japan) 
      and received service honoraria from Astellas Pharm, Otsuka Pham, and Takeda 
      Pharm. The remaining authors declare no conflict of interest.
EDAT- 2024/02/10 10:51
MHDA- 2024/02/10 10:52
PMCR- 2024/02/01
CRDT- 2024/02/10 01:03
PHST- 2023/12/16 00:00 [received]
PHST- 2024/01/20 00:00 [revised]
PHST- 2024/01/29 00:00 [accepted]
PHST- 2024/02/10 10:52 [medline]
PHST- 2024/02/10 10:51 [pubmed]
PHST- 2024/02/10 01:03 [entrez]
PHST- 2024/02/01 00:00 [pmc-release]
AID - jcm13030850 [pii]
AID - jcm-13-00850 [pii]
AID - 10.3390/jcm13030850 [doi]
PST - epublish
SO  - J Clin Med. 2024 Feb 1;13(3):850. doi: 10.3390/jcm13030850.